Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.37 (
CNPase
)
539
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the alteration of oligodendrocytes in comparison with that of astrocytes and microglia in the mouse striatum after
MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropridine) treatment under the same conditions using Western blot analysis and Immunohistochemistry. In our Western blot analysis, four administrations of
MPTP
at 2-h intervals to mice produced the remarkable loss of TH (tyrosine hydroxylase) protein levels in the striatum after 3 and 7 days. In contrast, GFAP (glial fibrillary acidic protein) and Iba-1 protein in the striatum showed a significant increase of GFAP and Iba-1 protein levels 3 and 7 days after
MPTP
treatment. On the other hand, the levels of
CNPase
(2', 3'-cyclic nucleotide 3'-phosphodiesterase) protein were decreased significantly in the striatum 3 and 7 days after
MPTP
treatment. In our immunohistochemical study, a significant decrease in the area of expression of
CNPase
-positive profiles was observed in the striatum 3 and 7 days after
MPTP
treatment. These results demonstrate that oligodendrocytes in the striatum are damaged after
MPTP
treatment. Thus our present findings provide valuable information for the pathogenesis of Parkinson's disease.
...
PMID:Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. 1767 28
